Conditions: Pulmonary Disease, Chronic Obstructive
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 644
Healthy volunteers: no

Brief summary:
This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD).

Detailed description:

Arms:
arm 1: Low dose inhaled orally once daily from the Respimat inhaler arm 2: Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler arm 3: High dose inhaled orally once daily from the Respimat inhaler

Interventions: intervention 1: Olodaterol (BI 1744) intervention 2: Olodaterol (BI 1744) intervention 3: Placebo
Intervention descriptions: intervention 1: Comparison of low and high doses on efficacy and safety in COPD patients intervention 2: Comparison of low and high doses on efficacy and safety in COPD patients intervention 3: Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler

Protocol document: